The majority of tumors in NSCLC patients are found to be p53-mutated or p53-deficient and rely only on the WEE1 G2 checkpoint for cell cycle arrest after treatment with DNA-damaging agents. The gene discussed is WEE1; the disease is non-small cell lung carcinoma.